一项研究霍雀五苓散改善骨髓增殖性肿瘤患者生活质量的疗效的初步研究。

A pilot study examining the efficacy of hochuekkito for improving quality of life in patients with myeloproliferative neoplasms.

机构信息

Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.

Department of Hematology, Juntendo University Shizuoka Hospital, Izunokunishi, Japan.

出版信息

Jpn J Clin Oncol. 2022 Aug 5;52(8):880-886. doi: 10.1093/jjco/hyac076.

DOI:10.1093/jjco/hyac076

PMID:35575284

Abstract

BACKGROUND

The prognosis of Philadelphia chromosome-negative myeloproliferative neoplasms is relatively favorable, but the quality of life can be severely affected by myeloproliferative neoplasm-related symptoms such as fatigue, pruritus, night sweats, bone pain, fever and weight loss. In this study, we administered hochuekkito, a traditional herbal medicine, to patients with myeloproliferative neoplasms and investigated whether there was a reduction in myeloproliferative neoplasm-related symptoms.

METHODS

We conducted a randomized parallel-group pilot study. Patients were assigned to a hochuekkito administration or non-hochuekkito administration group. Myeloproliferative neoplasm-related symptoms based on Myeloproliferative Neoplasm Symptom Assessment Form total symptom score and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 were examined before hochuekkito administration and 4 and 8 weeks after administration.

RESULTS

Among the 42 patients included in the analysis, 21 were assigned to the hochuekkito group and 21 were assigned to the control group. After administering hochuekkito, the median values of Myeloproliferative Neoplasms Symptom Assessment Form total symptom score at 4 and 8 weeks in the hochuekkito group demonstrated a decreasing trend; however, the difference between the two groups was not significant.

CONCLUSIONS

In this study, we were unable to demonstrate significant differences between the hochuekkito and control groups in terms of the efficacy of hochuekkito in treating myeloproliferative neoplasm-related symptoms. However, there were cases that presented prominent improvement in symptoms in the hochuekkito group. The only reported adverse event was grade 1 impaired hepatic function. Therefore, hochuekkito might be a therapeutic option for patients with severely affected quality of life due to myeloproliferative neoplasm-related symptoms.

摘要

背景

费城染色体阴性骨髓增殖性肿瘤的预后相对较好，但骨髓增殖性肿瘤相关症状，如疲劳、瘙痒、盗汗、骨痛、发热和体重减轻，会严重影响生活质量。在这项研究中，我们给骨髓增殖性肿瘤患者服用了一种传统的中草药—— hochuekkito，并研究了 hochuekkito 是否能减轻骨髓增殖性肿瘤相关症状。

方法

我们进行了一项随机平行组的初步研究。患者被分配到 hochuekkito 给药组或非 hochuekkito 给药组。在 hochuekkito 给药前以及给药后 4 周和 8 周，使用骨髓增殖性肿瘤症状评估表总症状评分和欧洲癌症研究与治疗组织生活质量核心 30 问卷评估骨髓增殖性肿瘤相关症状。

结果

在纳入分析的 42 例患者中，21 例分配到 hochuekkito 组，21 例分配到对照组。给予 hochuekkito 后，hochuekkito 组在 4 周和 8 周时骨髓增殖性肿瘤症状评估表总症状评分的中位数呈下降趋势；然而，两组之间的差异无统计学意义。

结论

在这项研究中，我们未能证明 hochuekkito 组在治疗骨髓增殖性肿瘤相关症状方面与对照组有显著差异。然而，hochuekkito 组有一些病例的症状明显改善。唯一报告的不良事件是 1 级肝功能受损。因此，hochuekkito 可能是那些因骨髓增殖性肿瘤相关症状而生活质量严重受影响的患者的一种治疗选择。